Introduction & Objective: Islet α cells have traditionally been maligned for contributing to hyperglycemia in diabetes but are increasingly recognized for their potential to promote β cell mass and function. The cellular mechanisms regulating proglucagon production and its subsequent processing into glucagon and/or glucagon-like peptide 1 (GLP-1) in α cells are incompletely understood. Autophagy, the process of recycling cellular components by lysosomal degradation, is essential for insulin production and β cell survival.

Methods: To investigate the role of autophagy in α cells, we deleted the key autophagosome protein Atg7 using the Cre-lox system in mice or CRISPR in αTC cells.

Results: Atg7 ΔGcg mice showed normal growth and oral glucose tolerance into adulthood but had impaired glucagon secretion following hypoglycemia by two months of age. Islet α cells in Atg7 ΔGcg mice became hypertrophic and vacuolated with age, but survived without a substantial decline in mass. Instead, pancreatic glucagon content was reduced in Atg7 ΔGcg mice (42.2 +/- 7.3 vs. 75.3 +/- 9.1 ng/g). Electron microscopy revealed α cells with fewer glucagon granules and dilated endoplasmic reticulum (ER), and increased expression of the ER chaperone BiP was confirmed in αTCΔAtg7 cells. This was associated with a decrease in the proglucagon processing hormone PC2, possibly limiting production of mature glucagon. Interestingly, total pancreatic GLP-1 content was increased in Atg7 ΔGcg mice (1351 +/- 114 vs. 891 +/- 75 pg/g) without changes in serum GLP-1 levels. Using the GLP-1 receptor antagonist exendin(9-39), we observed a similar impairment in oral glucose tolerance in Atg7 ΔGcg mice and littermate controls.

Conclusion: These data show that autophagy promotes classic α cell function by maintaining ER proteostasis and glucagon production. However, defective α cell autophagy does not entirely disrupt proglucagon-mediated signaling in vivo and may promote α cell GLP-1 production.

Disclosure

W. Zhu: None. L. Pan: None. A. Russo: None. R. Ray: None. B. Pederson: None. N. Shrestha: Employee; Regeneron Pharmaceuticals Inc. L. Qi: None. R.B. Reinert: None.

Funding

National Institutes of Health (K08DK129719, T32DK007245)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.